Skip to main content

Lymphocyte Teamwork in Tumor Rejection

  • Conference paper
  • First Online:
  • 1169 Accesses

Abstract

Immune responsiveness depends on a complex interplay between the elements of innate and adaptive immunity. Several recent studies in various models of immune rejection, including ours in a mouse tumor model, yield new insights into the adaptive control of innate effector functions. This chapter provides a discussion of key observations indicating an indispensable T cell help for innate antitumor immunity.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Virchow R. Handbuch der speciellen pathologie und therapie. Erlangen, 1; 1854.

    Google Scholar 

  2. Ehrlich P. Uber den jetztigen stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273–90.

    Google Scholar 

  3. Burnet F. Cancer – a biological approach. 1. The process of control. Br Med J. 1957;1:779–82.

    Article  PubMed  CAS  Google Scholar 

  4. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity [discussion]. In: Lawrence HS, editor. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959.

    Google Scholar 

  5. Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer. 1989;44:634–40.

    Article  PubMed  Google Scholar 

  6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.

    Article  PubMed  Google Scholar 

  7. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–65.

    Article  PubMed  CAS  Google Scholar 

  8. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482:400–4.

    Article  PubMed  CAS  Google Scholar 

  9. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32.

    Article  PubMed  CAS  Google Scholar 

  10. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med. 1991;173:1373–84.

    Article  PubMed  Google Scholar 

  11. Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J Immunol. 2004;172:5069–77.

    PubMed  CAS  Google Scholar 

  12. Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM. CD8 T cell help for innate antitumor immunity. J Immunol. 2007;179:6651–62.

    PubMed  CAS  Google Scholar 

  13. Shanker A, Buferne M, Schmitt-Verhulst AM. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology. 2010;129:41–54.

    Article  PubMed  CAS  Google Scholar 

  14. Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011;3:1143–66.

    Article  PubMed  CAS  Google Scholar 

  15. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011;60:1061–74.

    Article  PubMed  CAS  Google Scholar 

  16. Shanker A. Adaptive control of innate immunity. Immunol Lett. 2010;131:107–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

AS is supported by funds from the NIH grants U54 CA091408 (NCI), 5 U54 RR026140-03 (NCRR), 8 U54 MD007593-03 (NIMHD), and 5P50 CA 090949 (NCI).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anil Shanker .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer India

About this paper

Cite this paper

Shanker, A. (2012). Lymphocyte Teamwork in Tumor Rejection. In: Sabu, A., Augustine, A. (eds) Prospects in Bioscience: Addressing the Issues. Springer, India. https://doi.org/10.1007/978-81-322-0810-5_49

Download citation

Publish with us

Policies and ethics